Skip to main content

Transgenomic's Q1 Revenues Fall 21 Percent

NEW YORK (GenomeWeb News) – Transgenomic today reported that its first-quarter revenues fell 21 percent year over year, and the firm swung to a loss from a profit a year earlier.

The Omaha, Neb.-based pharmacogenomics firm brought in revenues of $5 million for the three-month period ended March 31, compared to $6.3 million for the first quarter of 2008.

"Unfortunately, like many companies today, we are also experiencing an impact from the overall economic slowdown," Transgenomic President and CEO Craig Tuttle said in a statement.

Tuttle added that the decline in revenues "was primarily the result of a slowdown in instrument orders compared to what we experienced throughout 2008." He noted, however, that revenues for the firm's Molecular Diagnostics Laboratory grew by $447,000 over the first quarter of 2008.

Transgenomic posted a net loss of $1 million, or $.02 per share, for the quarter compared to a slim profit of $122,000, or $.00 per share, for the first quarter of 2008.

Its R&D spending increased to $844,000 from $572,000, and its SG&A expenses were flat year over year at $3 million.

Transgenomic finished the quarter with $4.8 million in cash and cash equivalents.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.